加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$63.04
−US$0.75 · -1.18%
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
前收盘价
US$63.04
−US$0.75 · -1.18%
盘前
US$62.00
−US$1.04 · -1.65%
10月8日 8:16 ET
盘中时间采用ET。市场数据可能有所延迟。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日内区间
当前US$63.04
52周区间
当前US$63.04
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
8
估值过高
情绪
57
多空交织
风险
56
风险偏高
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日内区间
当前US$63.04
52周区间
当前US$63.04
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.8亿 USD | 3.34亿 USD | 2.8亿 USD | 3.22亿 USD | 2.96亿 USD |
| 销货成本 | 1.23亿 USD | 1.1亿 USD | 1.02亿 USD | 1.12亿 USD | 9738.9万 USD |
| 毛利 | 2.57亿 USD | 2.24亿 USD | 1.78亿 USD | 2.1亿 USD | 1.99亿 USD |
| 研究与开发 | 7142.9万 USD | 7240.5万 USD | 8186.6万 USD | 9038.8万 USD | 7652.5万 USD |
| 销售、一般及管理费用 | 2.1亿 USD | 2.06亿 USD | 2.01亿 USD | 1.96亿 USD | 1.52亿 USD |
| 营业费用 | 2.82亿 USD | 1.83亿 USD | 3.82亿 USD | 2.87亿 USD | 2.29亿 USD |
| 利息收入 | 917.4万 USD | 1176.5万 USD | 1186.7万 USD | 376.2万 USD | 16万 USD |
| 折旧和摊销 | 2041.6万 USD | 1975.7万 USD | 1982.4万 USD | 1600.7万 USD | 1188.5万 USD |
| 营业利润 | −2507.1万 USD | 4076.5万 USD | −2.03亿 USD | −7723.1万 USD | −2972.6万 USD |
| 净利润 | −2135.4万 USD | 5254.9万 USD | −1.9亿 USD | −7661.3万 USD | −3066.2万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$62.25
下跌空间 1.25%报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG9064.67万4.30%15.57亿 USD0.75%US$50.14-3.11%
State Street SPDR S&P Biotech ETFXBI8828.11万0.86%100.75亿 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM8551.27万0.11%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI7798.97万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 Growth ETFIWO3064.64万0.22%142.49亿 USD0.24%US$355.37-1.43%
Vanguard Extended Market ETFVXF3009.54万0.03%954亿 USD0.05%US$233.49-1.56%
Dimensional - US Small Cap ETFDFAS2545.69万0.07%336.6亿 USD0.31%US$77.92-1.38%
iShares Biotechnology ETFIBB2283.25万0.22%104.01亿 USD0.44%US$203.34+0.12%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
